Work

683P Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.079

Authors: P.V. Nuzzo, E. Adib, N. Weise, C. Curran, T. Stewart, D. Freeman, A.H. Nassar, S. Abou Alaiwi, Z. Bakouny, B.A. McGregor, T.K. Choueiri, R.K. Jain, R.R. McKay, G.P. Sonpavde

Institutions: Dana-Farber Cancer Institute, University of California San Diego, Moores Cancer Center, Brigham and Women's Hospital, Massachusetts General Hospital

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Amsterdam University Medical Centers, Universiteit Leiden, Radboud Universiteit, Leids Universitair Medisch Centrum, Radboud Universitair Medisch Centrum, Rheinische Friedrich-Wilhelms-Universität Bonn, RIKEN, Radboud Institute for Health Sciences

OpenAlex ID: W3201838745

FWCI:

Cites:

Cited by:

Related to: 10